New smart drug targets cancer cells while sparing healthy ones

NCT ID NCT07277270

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine, GSK5764227, that delivers a toxin directly to cancer cells to destroy them while leaving healthy cells alone. It is given together with standard treatments to people with advanced solid tumors like colorectal or prostate cancer. The main goals are to check safety, how the body handles the drug, and whether it can shrink or control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal neoplasm metastatic prostate carcinoma neoplasm prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Lake Success, New York, 11042, United States
GSK Investigational Site
RECRUITING

Tugun, Queensland, 4224, Australia
GSK Investigational Site
RECRUITING

Barcelona, 08035, Spain
GSK Investigational Site
RECRUITING

Madrid, 28034, Spain
GSK Investigational Site
RECRUITING

Madrid, 28050, Spain
GSK Investigational Site
RECRUITING

Málaga, 29010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.